Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities ; volume:51 ; number:1 ; year:2018 ; pages:337-355
Cellular physiology and biochemistry ; 51, Heft 1 (2018), 337-355

Creator: Hung, Wen-Yueh
Chang, Jer-Hwa
Cheng, Yu
Chen, Chi-Kuan
Chen, Ji-Qing
Hua, Kuo-Tai
Cheng, Chao-Wen
Hsiao, Michael
Chung, Chi-Li
Lee, Wei-Jiunn
Chien, Ming-Hsien

DOI: 10.1159/000495233

URN: urn:nbn:de:101:1-2018112823204596840543

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hung, Wen-Yueh
Chang, Jer-Hwa
Cheng, Yu
Chen, Chi-Kuan
Chen, Ji-Qing
Hua, Kuo-Tai
Cheng, Chao-Wen
Hsiao, Michael
Chung, Chi-Li
Lee, Wei-Jiunn
Chien, Ming-Hsien

Other Objects (12)

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell Lung Cancer Exhibits Antitumoral Activity

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell Lung Cancer Exhibits Antitumoral Activity

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell Lung Cancer Exhibits Antitumoral Activity

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell Lung Cancer Exhibits Antitumoral Activity

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell Lung Cancer Exhibits Antitumoral Activity

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell Lung Cancer Exhibits Antitumoral Activity

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Related objects

Reset password